This regimen demonstrated clinical benefit, with durable responses, reflected in an mOS of 6.6 (95% CI 4.5–8.7) months, an mPFS of 3.8 (95% CI 1.6–5.1), and a notably lower rate of severe neutropenia (7%, compared to 27% in the NAPOLI-1 trial), likely attributable to CXCR4 inhibition by motixafortide [29]. This evidence concerns the gene CXCR4 and Decreased total neutrophil count.